Cases of tuberculosis (TB) — an illness that kills more people than any other infectious disease — rose in the U.S. during 2022, per the Centers for Disease Control and Prevention (CDC). And some ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Tuberculosis (TB), one of the leading infectious disease killers ...

A new study published in the American Society for Microbiology journal Microbiology Spectrum demonstrates that a novel semi-synthetic compound can be derived from natural compounds to produce potent ...

Decades of reliance on the antibiotic rifampicin have fueled the rise of drug-resistant Mycobacterium tuberculosis (Mtb). But ...

An international consortium analyzed the genetic sequences and antibiotic susceptibility of more than 10,000 global Mycobacterium tuberculosis isolates. A massive analysis of more than 10,000 ...

Two treatment regimens for multidrug-resistant tuberculosis (TB), containing the first new drug to have been discovered for the disease in 40 years, are more effective than a previously recommended ...

In the face of growing antibiotic resistance among bacterial infections, scientists at The Hospital for Sick Children (SickKids) have delved into the molecular science behind treatment-resistant ...

Across Europe, tuberculosis (TB) is once again raising alarm, particularly the extensively drug-resistant form (XDR-TB), which is proving as deadly as before antibiotics were discovered. A large ...

Please provide your email address to receive an email when new articles are posted on . BPaL — bedaquiline, pretomanid and linezolid — is the first novel tuberculosis regimen in decades. BPaL shortens ...

The largest ever global study of tuberculosis has identified all the mutations conferring resistance to approved antimicrobials, setting the scene for more rational use of drugs, increasing ...